NEW YORK, Aug. 6-Third Wave Technologies is partnering with a Wisconsin health care provider and a Milwaukee clinical bioinformatics company to offer genetics-based preventive treatment of cardiovascular disease, the companies said today.
In the partnership, software from the bioinformatics company PointOne will first be used to screen Aurora Health Care's 72,000 cardiovascular patients for risk of deep vein thrombosis.
This initial screen will flag patients that may benefit from additional testing. Third Wave will then use genetic screening to test that group for two genetic variations associated with DVT. Those identified at particularly high risk can be treated with anti-clotting drugs or lifestyle modifications.
Third Wave's genetic tests will also be used to help Aurora Health Care physicians judge which patients should be treated with drugs, and choose the dosages of these medications.
In DVT, blood forms clots in the leg veins and can travel to the heart or lung with fatal results. Many cases result from surgery or prolonged illness.
Third Wave Technologies is a gene analysis equipment and service company based in Madison, Wis. Aurora Health Care is a non-profit Wisconsin health care network based in Milwaukee.